Fjarde AP Fonden Fourth Swedish National Pension Fund Raises Position in DexCom, Inc. $DXCM

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 53.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 169,194 shares of the medical device company’s stock after purchasing an additional 59,150 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in DexCom were worth $10,625,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Gradient Investments LLC grew its stake in shares of DexCom by 13.8% during the 4th quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock worth $22,035,000 after acquiring an additional 40,343 shares during the period. Nordea Investment Management AB raised its stake in DexCom by 118.6% in the 4th quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock valued at $16,988,000 after acquiring an additional 137,986 shares during the period. Banque Pictet & Cie SA raised its stake in DexCom by 58.2% in the 4th quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock valued at $7,289,000 after acquiring an additional 40,411 shares during the period. Holocene Advisors LP purchased a new stake in DexCom during the third quarter valued at about $163,964,000. Finally, Aberdeen Group plc lifted its holdings in DexCom by 9.0% during the fourth quarter. Aberdeen Group plc now owns 530,363 shares of the medical device company’s stock valued at $35,200,000 after purchasing an additional 43,990 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Citigroup reiterated a “buy” rating and issued a $84.00 target price (up from $79.00) on shares of DexCom in a research note on Thursday, May 28th. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Monday, May 18th. BTIG Research reaffirmed a “buy” rating and issued a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. UBS Group set a $95.00 price objective on shares of DexCom in a research note on Wednesday, June 10th. Finally, Bank of America reduced their price objective on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $84.88.

Insider Activity at DexCom

In related news, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the sale, the director owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 46,694 shares of company stock valued at $3,343,977 in the last quarter. 0.28% of the stock is currently owned by company insiders.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $71.25 on Friday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The company has a market cap of $27.49 billion, a P/E ratio of 30.45, a P/E/G ratio of 1.17 and a beta of 1.45. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The business has a 50-day simple moving average of $68.31 and a two-hundred day simple moving average of $68.17.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the business posted $0.32 earnings per share. The company’s revenue was up 15.0% on a year-over-year basis. Research analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.